文献速递垂体与肾上腺疾病

肾上腺皮质肿瘤的RNA测序与体细胞突变状态:新的发病机制见解

RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该横断面研究对59例肾上腺皮质肿瘤(包括库欣综合征皮质醇分泌腺瘤、轻度自主皮质醇分泌腺瘤、无功能腺瘤和肾上腺皮质癌)进行RNA测序,分析转录组与已知遗传背景的相关性。发现轻度自主皮质醇分泌腺瘤与无功能腺瘤转录组相似,而多数库欣综合征皮质醇分泌腺瘤聚为一类,并识别出新的基因融合。

要点

  • 轻度自主皮质醇分泌腺瘤与无功能腺瘤转录组特征相似,与遗传背景无关。
  • 多数库欣综合征皮质醇分泌腺瘤转录组聚为一类,包括PRKACA突变者。
  • 发现新基因融合如AKAP13-PDE8A,提示cAMP/PKA或Wnt/β-catenin通路未知改变可能参与发病。

核心结论

  • 轻度自主皮质醇分泌腺瘤与无功能腺瘤转录组相似,而多数库欣综合征皮质醇分泌腺瘤聚为一类。
  • cAMP/PKA或Wnt/β-catenin通路的未知分子改变可能参与肾上腺皮质肿瘤发病。

研究设计与样本

  • 横断面研究,收集欧洲肾上腺肿瘤研究网络大学医院59例肾上腺皮质肿瘤患者的冷冻组织。
  • 包括26例库欣综合征皮质醇分泌腺瘤、17例轻度自主皮质醇分泌腺瘤、9例无功能腺瘤和7例肾上腺皮质癌。
  • 进行RNA测序分析基因表达、长链非编码RNA表达和基因融合,并与靶向Sanger测序、靶向panel或全外显子测序定义的遗传背景关联。

主要发现

  • 腺瘤转录组分析识别2个主要聚类:聚类1(n=32)主要由轻度自主皮质醇分泌腺瘤(46.9%病例有CTNNB1突变或无驱动突变)和8/9例无功能腺瘤组成。
  • 聚类2(n=18)包含83.3%病例有或无驱动突变的库欣综合征皮质醇分泌腺瘤,包括所有PRKACA突变的库欣综合征皮质醇分泌腺瘤。
  • 2例库欣综合征皮质醇分泌腺瘤(1例CTNNB1突变,1例GNAS突变)单独聚类且相对接近肾上腺皮质癌。
  • 长链非编码RNA分析能很好区分腺瘤与肾上腺皮质癌。
  • 发现新基因融合,包括1例无驱动突变的库欣综合征皮质醇分泌腺瘤样本中的AKAP13-PDE8A。

临床怎么用

  • 转录组聚类有助于区分肾上腺皮质肿瘤亚型,轻度自主皮质醇分泌腺瘤与无功能腺瘤分子特征相似。
  • 长链非编码RNA表达谱可用于辅助鉴别腺瘤与肾上腺皮质癌。
  • 识别出的基因融合如AKAP13-PDE8A为潜在发病机制研究提供线索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pathogenesis of autonomous steroid secretion and adrenocortical tumorigenesis remains partially obscure. OBJECTIVE: To investigate the relationship between transcriptome profile and genetic background in a large series of adrenocortical tumors and identify new potential pathogenetic mechanisms. DESIGN: Cross-sectional study. SETTING: University Hospitals of the European Network for the Study of Adrenal Tumors (ENSAT). PATIENTS: We collected snap-frozen tissue from patients with adrenocortical tumors (n = 59) with known genetic background: 26 adenomas with Cushing syndrome (CS- cortisol-producing adenoma [CPA]), 17 adenomas with mild autonomous cortisol secretion (MACS-CPAs), 9 endocrine-inactive adenomas (EIAs), and 7 adrenocortical carcinomas (ACCs). INTERVENTION: Ribonucleic acid (RNA) sequencing. MAIN OUTCOME MEASURES: Gene expression, long noncoding RNA (lncRNA) expression, and gene fusions. Correlation with genetic background defined by targeted Sanger sequencing, targeted panel- or whole-exome sequencing. RESULTS: Transcriptome analysis identified 2 major clusters for adenomas: Cluster 1 (n = 32) mainly consisting of MACS-CPAs with CTNNB1 or without identified driver mutations (46.9% of cases) and 8/9 EIAs; Cluster 2 (n = 18) that comprised CP-CPAs with or without identified driver mutation in 83.3% of cases (including all CS-CPAs with PRKACA mutation). Two CS-CPAs, 1 with CTNNB1 and 1 with GNAS mutation, clustered separately and relatively close to ACC. lncRNA analysis well differentiate adenomas from ACCs. Novel gene fusions were found, including AKAP13-PDE8A in one CS-CPA sample with no driver mutation. CONCLUSIONS: MACS-CPAs and EIAs showed a similar transcriptome profile, independently of the genetic background, whereas most CS-CPAs clustered together. Still unrevealed molecular alterations in the cAMP/PKA or Wnt/beta catenin pathways might be involved in the pathogenesis of adrenocortical tumors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Di Dalmazi G, Altieri B, Scholz C, et al. RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. J Clin Endocrinol Metab. 2020. PMID: 32875319. doi:10.1210/clinem/dgaa616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。